Evidence map›Paper›PMID 31819826›Full record

ArticleJournal of clinical imaging science2019

Axumin Positron Emission Tomography: Novel Agent for Prostate Cancer Biochemical Recurrence.

Swachchhanda Songmen, Pankaj Nepal, Thomas Olsavsky, Joshua Sapire

2 registry-linked trialsOpen access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical imaging science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05553041 early_phase1recruitingnot on this mapstarted 2024, after this paper: background citation

Evaluation of 18F-Fluciclovine PET-MRI to Differentiate Tumor Progression From Post-treatment Changes in Pediatric High-grade Glioma (HGG)

TypeinterventionalSponsorChildren's Hospital of PhiladelphiaRan2024 to 2027Enrolled30ConditionsGlioma, High Grade Glioma, Glioma, Malignant, Glioma IntracranialArms18F-Fluciclovine PET-MRI
NCT05555550 early_phase1recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluation of 18F-Fluciclovine PET-MRI as a Biomarker of Response in Pediatric and Young Adult Patients With Low Grade Gliomas (LGG)

TypeinterventionalSponsorChildren's Hospital of PhiladelphiaRan2026 to 2027Enrolled30ConditionsGlioma, Low-grade Glioma, Low Grade Glioma of Brain, Glioma, MalignantArms18F-Fluciclovine
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Swachchhanda SongmenDepartment of Radiology, St. Vincent's Medical Center, Bridgeport, Connecticut, United States.
Pankaj NepalDepartment of Radiology, St. Vincent's Medical Center, Bridgeport, Connecticut, United States.
Thomas OlsavskyDepartment of Radiology, St. Vincent's Medical Center, Bridgeport, Connecticut, United States.
Joshua SapireDepartment of Radiology, St. Vincent's Medical Center, Bridgeport, Connecticut, United States.
St. Vincent's Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer remains one of the top common cancers in terms of incidence and cancer-related deaths. Approximately 1/3

Indexed as

Axumin (18F-fluciclovine)Biochemical recurrencePositron emission tomographyProstate cancerProstate-specific antigen

Identifiers

PMID31819826
PMCPMC6884981
OpenAlexW2988773936

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.